Table 1.

Patient characteristics and their association with OS

Patient characteristics	Total (N=53)	Cox hazard model
		HR	95% CI	P value
Age (years), mean (SD)	69.7 (8.5)	1.23	0.88 to 1.74	0.232
Sex, n (%)
Female	13 (25)	1
Male	40 (75)	0.92	0.44 to 1.92	0.826
Smoking, n (%)
Former	40 (75)	1
Never	13 (25)	1.46	0.71 to 3.01	0.318
Performance Status, n (%)
0–1	38 (71)	1
2–3	15 (29)	2.17	1.06 to 4.44	0.043
Stage, n (%)
Stage III (recurrent after chemoradiotherapy)	7 (13)	1
Recurrent after surgery	14 (26)	2.25	0.47 to 10.72	0.308
Stage IV	32 (60)	4.85	1.14 to 20.67	0.033
Histology, n (%)
Non-squamous	38 (72)	1
Squamous	15 (28)	1.38	0.65 to 2.92	0.410
Driver mutation, n (%)
Wild Type	41 (77)	1
EGFR (Epidermal growth factor receptor)	11 (21)	0.64	0.26 to 1.56	0.306
ALK (Anaplastic lymphoma kinase)	1 (2)	(EGFR or ALK/WT)
Tumor PD-L1 expression, n (%)
0%–49%	21 (45)
50%–100%	26 (55)	1.23	0.60 to 2.51	0.232
Treatment line, n (%)
1st line	20 (38)	1
2nd line	22 (42)	0.76	0.36 to 1.60	0.471
3rd line	7 (13)	0.75	0.30 to 1.88	0.540
4th line	2 (4)	(3rd line or later/1st line)
6th and 7th lines	2 (4)
PD-1 blocker, n (%)
Nivolumab	25 (47)	1
Pembrolizumab	28 (53)	1.37	0.70 to 2.66	0.358
Blood test, mean (SD)
Albumin (g/dL)	3.42 (0.61)	0.57	0.38 to 0.85	0.005
LDH (lactate dehydrogenase, U/L)	2634 (118)	1.13	0.81 to 1.49	0.448
White blood cell (/μL)	7513 (3357)	1.35	0.98 to 1.75	0.062
Lymphocyte (/μL)	1354 (615)	0.58	0.38 to 0.86	0.006
Neutrophil (/μL)	5476 (2969)	1.50	1.10 to 1.97	0.011
Eosinophil (/μL)	176 (178)	0.80	0.52 to 1.15	0.248
Monocyte (/μL)	477 (223)	1.49	1.05 to 2.02	0.027
Neutrophil:lymphocyte ratio	4.94 (3.56)	1.72	1.27 to 2.25	<0.001

Categorical variables are shown as the distribution of corresponding patient numbers. Continuous variables are shown as mean and SD values.

Univariate analysis was conducted using the Cox proportional hazard model for OS. HR, 95% CI.

ALK, anaplastic lymphoma kinase; LDH, lactate dehydrogenase; OS, overall survival; PS, performance status; WT, wild type.